{
  "docId": "019de075-7539-774f-abd7-26734f481c17",
  "docSlug": "efb32a48c20b71d9dd70ea37e2f1bc4b",
  "documentTitle": "argenx SE | Investor Presentation Deck | 26 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 26,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_messages",
  "function": "establish_context",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7539-774f-abd7-26734f481c17/5",
  "deckHref": "/decks/019de075-7539-774f-abd7-26734f481c17",
  "deckJsonHref": "/decks/019de075-7539-774f-abd7-26734f481c17.json",
  "deckAnchorHref": "/decks/019de075-7539-774f-abd7-26734f481c17#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.34,
        "x": 0.33,
        "y": 0.25
      },
      "kind": "callout",
      "text": "NOW TWO FDA-APPROVED PRODUCTS",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2abd31f-4748-4e47-9f13-7ad543e207b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.55,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous Injection 180 mg/mL and 2000 U/mL vial",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3b64eca-8851-4db4-bb0d-3fa1ae97373a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.15,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "VYVGART (efgartigimod alfa-fcab) Injection for Intravenous Use 400 mg/20 mL vial",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3ee4a09-0227-4424-8513-72c7a4901b67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.1,
        "y": 0.75
      },
      "kind": "subtitle",
      "text": "VYVGART and VYVGART Hytrulo are indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "516ce18d-5123-4186-835b-0ab59a7613d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.25,
        "y": 0.05
      },
      "kind": "title",
      "text": "VYVGART for Generalized Myasthenia Gravis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac636dcf-88f8-4de5-a654-adce322f9951",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 1,
      "beatId": "f0ed706d-de8c-40ed-bdc7-8a9c1fd7530d",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Setup",
      "beatSlug": "setup",
      "evidence": "The initial slides introduce the company, its mission, and key messages.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}